Related Experiment Video
Updated: Jan 4, 2026
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
Published on: January 12, 2017
[Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer]
A Afshar-Oromieh1, I Alberts2, C Sachpekidis2
1Klinik für Nuklearmedizin, Inselspital Bern, Freiburgstraße 18, 3010, Bern, Schweiz. ali.afshar@insel.ch.
Background:
Since their clinical introduction in 2011, PSMA-PET/CT (PSMA: prostate-specific membrane antigen) as well as PSMA therapy of prostate cancer (PC) have spread rapidly worldwide.
Objectives:
To summarize the current knowledge about both PSMA-PET/CT and PSMA therapy of PC.
Methods:
The knowledge derived from the literature as well as the authors' experiences were collected in this review.
Results:
PSMA-PET/CT demonstrates a very high sensitivity and specificity for the detection of recurrent PC as well as for the primary staging of intermediate- and high-risk PC. PSMA therapy shows promising results in third-line treatment for patients with castration-resistant, metastatic PC.
Conclusions:
PSMA-PET/CT is meanwhile established as the gold standard for the detection of recurrent PC and is in the process of assuming the same role for primary staging of intermediate- to high-risk PC. PSMA therapy serves as a promising third-line therapy in an increasing number of centers.
More Related Videos
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013